CLSI Antimicrobial Susceptibility Testing
Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species
8
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI Breakpoints
8
Next Generation Antimicrobial Susceptibility Testing
7
LABORATORY METHODOLOGIES FOR BACTERIAL ANTIMICROBIAL SUSCEPTIBILITY TESTING
11
Antimicrobial susceptibility testing in biofilm-growing bacteria
10
CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests
10
Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24 Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values
6
Antimicrobial susceptibility of strains of Enterobacteriaceae isolated from bloodstream infections using current CLSI and EUCAST breakpoints
5
Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations
20
Point Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility ResultsPoint Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility ResultsPoint Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility ResultsPoint Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results
6
Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan
7
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints
7
Critical Assessment of Issues Applicable to Development of Antimicrobial Susceptibility Testing Breakpoints
6
Multilaboratory Evaluation of Disk Diffusion Antimicrobial Susceptibility Testing of Neisseria meningitidis Isolates
11
Systems Approach to Improving Antimicrobial Susceptibility Testing in Clinical Laboratories in the United States
5
Assessment of Etest as an Alternative to Agar Dilution for Antimicrobial Susceptibility Testing of Neisseria gonorrhoeae
6
Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Staphylococcus spp and Enterococcus spp
6
Rapid Antimicrobial Susceptibility Testing Using Forward Laser Light Scatter Technology
6
Antimicrobial Susceptibility Testing through Image Analysis
76
Theoretical Investigation on Antimicrobial Susceptibility Testing Methods
15